Last 28 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.24 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.99 | 5.36 | 25.44 | 9.19 | 9.45 | 9.79 | 9.64 | 25.87 | 18.66 | 10.76 | 14.09 | 11.82 | 3.01 | 13.15 | 12.21 | 15.94 | 13.47 | 31.44 | 40.18 | 296.47 | 3140.35 |
| — | -45.2% | +164.0% | -64.5% | -49.4% | -9.0% | -31.6% | +118.9% | +520.9% | -18.1% | +15.5% | -25.8% | -77.7% | -58.2% | -69.6% | -94.6% | -99.6% | -91.1% | -90.5% | -25.2% | — | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2381.49 | 14.70 | 11.85 | 8.70 | 8.73 | 6.36 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +27183.8% | +131.1% | +214.1% | +124.5% | +220.7% | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.58 | 17.91 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.2% | 100.0% | 92.7% | 91.3% | -145.3% | 88.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 85.2% | -50.2% | -422.4% | 100.0% | -574.2% | -305.9% | -478.5% | -525.2% | -3050.5% | -49885.4% |
| — | +13.5% | -7.3% | -8.7% | -245.3% | -11.9% | 0.0% | +17.3% | +299.2% | +123.7% | 0.0% | +114.8% | +83.6% | +11.7% | +119.0% | +81.2% | +99.4% | +92.7% | +91.9% | -2354.1% | -49985.4% | |
| Operating Margin | -265.6% | -54.8% | -660.3% | -211.9% | -226.9% | -279.2% | -385.0% | -840.5% | -305.5% | -386.6% | -558.3% | -441.3% | -97.7% | -572.4% | -627.6% | -762.1% | -426.0% | -650.1% | -709.3% | -3938.6% | -64051.2% |
| — | +80.4% | -71.5% | +74.8% | +25.7% | +27.8% | +31.0% | -90.5% | -212.6% | +32.5% | +11.0% | +42.1% | +77.1% | +11.9% | +11.5% | +80.7% | +99.3% | +92.2% | +91.2% | +52.4% | -520.1% | |
| Net Margin | -240.3% | -44.7% | -608.4% | -234.3% | -194.4% | -237.3% | -316.4% | -682.9% | -244.9% | -333.6% | -495.4% | -417.9% | -82.1% | -526.6% | -574.3% | -690.4% | -388.4% | -608.3% | -686.6% | -4087.4% | -63609.8% |
| — | +81.1% | -92.3% | +65.7% | +20.6% | +28.9% | +36.1% | -63.4% | -198.4% | +36.7% | +13.7% | +39.5% | +78.9% | +13.4% | +16.4% | +83.1% | +99.4% | +92.7% | +91.5% | +50.6% | -519.9% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -236.4% | -71.6% | -45.5% | -31.8% | -32.8% | -28.2% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -621.4% | -154.3% | -125.8% | -87.7% | +89.8% | — | |
| ROA | -30.8% | -3.4% | -9.5% | -10.7% | -7.4% | -7.4% | -6.9% | -6.6% | -6.0% | -7.9% | -9.2% | -8.0% | -4.4% | -8.3% | -7.8% | -6.9% | -5.8% | -5.8% | -5.3% | -8.3% | -13.2% |
| — | +54.3% | -36.3% | -63.2% | -22.4% | +6.1% | +25.0% | +18.1% | -36.7% | +4.9% | -18.0% | -16.8% | +24.1% | -43.2% | -46.8% | +16.6% | +56.2% | +45.2% | +43.6% | +20.8% | +14.8% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -136.2% | — | — | -26.8% | -24.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -466.5% | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 459.88 | 2.19 | 1.15 | 0.78 | 0.60 | 0.99 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +76272.1% | +121.5% | +46.6% | +18.7% | +7.4% | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.73 | 3.36 | 2.92 | 2.73 | 2.16 | 2.62 | 3.16 | 3.73 | 4.77 | 5.69 | 4.06 | 4.11 | 5.10 | 5.13 | 5.75 | 6.37 | 6.84 | 8.34 | 8.91 | 9.44 | 6.42 |
| — | +28.3% | -7.6% | -26.7% | -54.7% | -54.0% | -22.2% | -9.3% | -6.5% | +11.0% | -29.3% | -35.4% | -25.4% | -38.5% | -35.5% | -32.6% | +6.5% | -5.4% | -12.0% | -6.7% | +76.0% | |
| Quick Ratio | 2.73 | 3.36 | 2.92 | 2.73 | 2.16 | 2.62 | 3.16 | 3.73 | 4.77 | 5.69 | 4.06 | 4.11 | 5.10 | 5.13 | 5.75 | 6.37 | 6.84 | 8.34 | 8.91 | 9.44 | 6.42 |
| — | +28.3% | -7.6% | -26.7% | -54.7% | -54.0% | -22.2% | -9.3% | -6.5% | +11.0% | -29.3% | -35.4% | -25.4% | -38.5% | -35.5% | -32.6% | +6.5% | -5.4% | -12.0% | -6.7% | +76.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -65.92 | -52.63 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FHTX stock.
Foghorn Therapeutics Inc.'s current P/E is -2.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Foghorn Therapeutics Inc.'s current operating margin is -265.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Foghorn Therapeutics Inc.'s business trajectory between earnings reports.